SRZNW
Surrozen, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
−60.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 11.5M | 3.5M | 10.7M | — | 12.5M |
| Cost of Revenue | 65.0K | 537.0K | — | 27.2M | 3.3M |
| Gross Profit | 11.4M | 2.9M | 10.7M | (27.2M) | 9.2M |
| Operating Expenses | |||||
| R&D Expense | 34.6M | 29.4M | 21.1M | 27.2M | 37.0M |
| SG&A Expense | 21.3M | 16.2M | 15.1M | 15.8M | 19.8M |
| General & Admin Expense | 21.3M | 16.2M | 15.1M | 15.8M | 19.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (537.0K) | — | (24.5M) | (3.3M) |
| Total Operating Expenses | 55.8M | 45.0M | 36.2M | 18.6M | 53.6M |
| Cost and Expenses | 55.9M | 45.6M | 36.2M | 45.8M | 56.8M |
| Operating Income (EBIT) | (44.4M) | (42.1M) | (25.5M) | (45.8M) | (44.3M) |
| Non-Operating | |||||
| Interest Income | 3.5M | 3.0M | 1.7M | 2.3M | 781.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.5M | 3.0M | 1.7M | 2.3M | 781.0K |
| Other Non-Op Income/Expense | (287.8M) | (199.9M) | (38.0M) | 2.7M | 8.3M |
| Non-Operating Income (excl Interest) | 287.8M | 199.9M | 38.0M | (2.7M) | (8.3M) |
| EBT (Pre-Tax Income) | (332.1M) | (242.0M) | (63.6M) | (43.0M) | (36.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (332.1M) | (242.0M) | (63.6M) | (43.0M) | (36.0M) |
| Earnings from Cont. Ops | (332.1M) | (242.0M) | (63.6M) | (43.0M) | (36.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (391.7M) | (242.0M) | (63.6M) | (43.0M) | (36.0M) |
| Per Share | |||||
| Basic EPS | ($41.13) | ($32.37) | ($21.67) | ($21.33) | ($15.55) |
| Diluted EPS | ($44.29) | ($32.37) | ($21.67) | ($21.33) | ($15.55) |
| Revenue Per Share | $0.99 | $0.46 | $3.63 | $0.00 | $5.40 |
| Shares | |||||
| Basic Shares Outstanding | 11.7M | 7.5M | 2.9M | 2.0M | 2.3M |
| Diluted Shares Outstanding | 23.1M | 7.5M | 2.9M | 2.0M | 2.3M |
| Profitability Metrics | |||||
| EBITDA | (331.9M) | (241.5M) | (62.1M) | (41.1M) | (34.0M) |
| D&A | 222.0K | 537.0K | 1.4M | 1.9M | 2.0M |
| EBIT | (332.1M) | (242.0M) | (63.6M) | (43.0M) | (36.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026